Core Viewpoint - Olema Pharmaceuticals, Inc. is focused on developing targeted therapies for breast cancer and will present at the TD Cowen 46 Annual Health Care Conference on March 3, 2026 [1] Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company dedicated to improving outcomes for breast cancer patients and is advancing a pipeline of novel therapies [3] - The lead product candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in two Phase 3 clinical trials [3] - Olema is also developing OP-3136, a potent KAT6 inhibitor, which is in a Phase 1 clinical study [3] - The company is headquartered in San Francisco with operations in Cambridge, Massachusetts [3]

Core Viewpoint - Olema Pharmaceuticals, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its focus on targeted therapies for breast cancer and its ongoing clinical trials [1] Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company dedicated to improving outcomes for breast cancer patients through innovative therapies [3] - The company is advancing a pipeline that includes palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in two Phase 3 clinical trials [3] - Olema is also developing OP-3136, a potent lysine acetyltransferase 6 inhibitor, which is in a Phase 1 clinical study [3] - The company is headquartered in San Francisco with operations in Cambridge, Massachusetts [3]

Core Insights - Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other conditions [3] - The company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025 [1] Company Overview - Olema Oncology is dedicated to transforming the standard of care for patients with breast cancer, advancing a pipeline of novel therapies [3] - The lead product candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in two Phase 3 clinical trials [3] - Olema is also developing OP-3136, a potent lysine acetyltransferase 6 inhibitor, which is in a Phase 1 clinical study [3] - The company is headquartered in San Francisco with operations in Cambridge, Massachusetts [3]

Core Insights - Olema Pharmaceuticals has aligned with the FDA to select a 90 mg dose of palazestrant for the Phase 3 OPERA-01 trial in ER+/HER2- metastatic breast cancer [1][2] - The OPERA-01 trial results are expected to be presented at the ASCO Annual Meeting from May 30 to June 3, 2025, with top-line data anticipated in 2026 and a potential commercial launch in 2027 [2][4] Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer, particularly through its lead product candidate, palazestrant (OP-1250) [4][5] - Palazestrant is a novel small molecule that acts as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader, currently being evaluated in multiple clinical trials [3][5] Clinical Trials - The OPERA-01 trial is a randomized, open-label Phase 3 study comparing palazestrant monotherapy to standard endocrine therapy for patients with advanced ER+/HER2- breast cancer [2][4] - Palazestrant has received FDA Fast Track designation for treating ER+/HER2- metastatic breast cancer that has progressed after endocrine therapy and at least one line of treatment with a CDK4/6 inhibitor [3][4]